Not to be used in type 1 DM or diabetic ketoacidosis. Hypoglycaemia may occur w/ administration of higher than the required dose. Acute pancreatitis; GI adverse reactions. May reduce absorption rate of orally administered drugs. Patients receiving oral drugs that require rapid GI absorption, requires careful clinical monitoring or have a narrow therapeutic ratio. Potential risk of dehydration. Ab formation against insulin glargine &/or lixisenatide. K shift from extracellular to intracellular space leading to hypokalemia. Never use a syringe to draw the medicine from the cartridge in the pre-filled pen into a syringe. Fluid retention may lead to or exacerbate heart failure. Switch from glucagon-like peptide-1 receptor agonist. Concomitant use w/ dipeptidyl peptidase-4 inhibitors, sulfonylureas, glinides, pioglitazone & sodium-glucose co-transporter-2 inhibitors. Contains metacresol which may cause allergic reactions. Not recommended in patients w/ severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. Not recommended in women of childbearing potential not using contraception. Pregnancy. Not to be used during breast-feeding.